The ABPI has appointed IT solutions providers IMS Health and C&C Group to support delivery of its disclosure database, which will make pharmaceutical industry payments to individual healthcare professionals and healthcare organisations public from June 2016.
Both companies are specialists in providing pharmaceutical and healthcare IT business services worldwide and will provide the ABPI with the technical support required to compile and present data from UK pharmaceutical companies on a single, searchable platform accessed via the ABPI's website.
The platform will use IMS Health's OneKey CRM database and Aggregate Spend 360 software alongside a bespoke portal developed by C&C Group. When launched by 30 June 2016 the platform will report payments made to individual, named healthcare professionals and healthcare organisations as part of a Europe-wide programme to ensure greater transparency of relationships between industry and healthcare professionals*.
Mark Smyth, ABPI's IT Business Systems Manager, said: "Transparency is high on the agenda for the pharmaceutical industry worldwide. Delivering the single platform for pharmaceutical companies here in the UK is one of the ABPI's major priorities for 2015-16 and we are pleased to be working with two well-established businesses with their roots firmly in the industry in order to deliver this important project."
"IMS Health welcomes the opportunity to support this important transparency initiative," said Tim Sheppard, UK General Manager, IMS Health. "The powerful combination of our data assets and technology service offerings will help provide greater insight into the valuable role that the pharmaceutical industry plays in supporting healthcare professionals in their efforts to improve patient outcomes."
Jon Edwards, C&C Group's Head of Pharmaceutical and Healthcare Service Delivery, added: "We are delighted to be working with the ABPI and IMS on this important project delivering transparency within a technical framework of reliability, accuracy and security."
*This is enshrined in the EFPIA Disclosure Code which has been adopted across 33 European countries and incorporated into the ABPI Code of Practice, administered by the Prescription Medicines Code of Practice Authority (PMCPA).
From 30 June, 2016 transfers of value to individual named healthcare professionals made during 2015 will cover four categories:
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with comprehensive solutions to measure and improve their performance. By applying sophisticated analytics and proprietary application suites hosted on the IMS One intelligent cloud, the company connects more than 10 petabytes of complex healthcare data on diseases, treatments, costs and outcomes to help its clients run their operations more efficiently. Drawing on information from 100,000 suppliers and on insights from more than 45 billion healthcare transactions processed annually, IMS Health's approximately 10,000 employees drive results for healthcare clients globally. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community. Additional information is available at www.imshealth.com.
As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes.
ABPI Press Office Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441 Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811 Email: email@example.com
Tor Constantino IMS Health TConstantino@us.imshealth.com www.imshealth.com
Jonathan Edwards C&C Group firstname.lastname@example.org www.candc-uk.com